[ Price : $8.95]
Salix says it plans to submit an NDA for rifaximin for treating non-constipation irritable bowel syndrome in the first half of 201...[ Price : $8.95]
Federal Register Notice: FDA releases a guidance, Patient-Reported Outcome Measures Use in Medical Product Development to Support ...[ Price : $8.95]
An FDA final rule will require producers of PET drugs to submit NDAs or ANDAs for their drugs starting in two years.[ Price : $8.95]
The Obama administration sends mixed signals on whether it supports legislation to permit drug importation.[ Price : $8.95]
Repligen reports mixed results from a Phase 3 clinical trial evaluating RG1068, a synthetic human secretin intended to improve mag...[ Price : $8.95]
Protalix Biotherapeutics submits an NDA for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) for treati...[ Price : $8.95]
Federal Register Notice: FDA establishes a public docket to obtain suggestions on elements for an approved tobacco retailer traini...[ Price : $8.95]
FDA issues a guidance with its thinking on how PET drug manufacturers can comply with cGMP regulations.